# A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Study · id `cardio:ct-nct01065454` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01065454](<https://clinicaltrials.gov/study/NCT01065454>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01065454

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 202 participants.

## Technical summary

Registry record NCT01065454. Randomized; quadruple masking; primary purpose treatment. Start 2010-04-14 (actual); primary completion 2012-06-06 (actual). Results posted on 2013-12-25.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 202 participants (enrolled count; ClinicalTrials.gov record NCT01065454, source copy `cardio:ctgov-nct01065454-2026-08-20`, retrieved 2026-10-31)
- Started: 2010-04-14 (actual) (ClinicalTrials.gov record NCT01065454, source copy `cardio:ctgov-nct01065454-2026-08-20`, retrieved 2026-10-31)
- Primary completion: 2012-06-06 (actual) (ClinicalTrials.gov record NCT01065454, source copy `cardio:ctgov-nct01065454-2026-08-20`, retrieved 2026-10-31)
- Completion: 2025-07-23 (actual) (ClinicalTrials.gov record NCT01065454, source copy `cardio:ctgov-nct01065454-2026-08-20`, retrieved 2026-10-31)
- Results first posted: 2013-12-25 (ClinicalTrials.gov record NCT01065454, source copy `cardio:ctgov-nct01065454-2026-08-20`, retrieved 2026-10-31)
- Countries: United States; Australia; Austria; Belgium; Canada; China; Czechia; Denmark; France; Germany; Italy; Japan; Netherlands; Poland; Singapore; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT01065454, source copy `cardio:ctgov-nct01065454-2026-08-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01065454-2026-08-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
- Acronym: LEPHT
- Condition: Hypertension, Pulmonary
- Condition: Ventricular Dysfunction, Left
- Intervention (Drug): Riociguat (Adempas, BAY63-2521)
- Intervention (Drug): Riociguat (Adempas, BAY63-2521)
- Intervention (Drug): Riociguat (Adempas, BAY63-2521)
- Intervention (Drug): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study (`cardio:pubmed-23775260`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1e372135436a983a490c8f880df9bbe81614e94511f768238eeb0ae5b3548915
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
